Contacts: Marlene Mandella (Intake Coordinator) & Jenny Ricks (Program Coordinator)
Dr. Christos Galanopoulos
Dr. Randy Zuckerman
Dr. Nick Manguso Reno, NV
Contact: Eng. Mohamed A. Raouf
Director of New Technologies
Advanced Surgical Technologies
Mobile: +966-56-6053333
Email: mohamed.raouf@gulfmedical.com and gulfmed@gulfmedical.com
Contact: Eng. Tamer Alsmadi
Business Unit Manager
Advanced Surgical Technologies
Email: tameralsmadi@naghimedical.com and naghi@naghimedical.com
Contact: Transmedic China Ltd.
Unit 1502, Yen Sheng Centre,
64 Hoi Yuen Road,
Kwun Tong, Kowloon,
Hong Kong
Phone: +852 2107 4668
Fax: +852 2107 4669
Email: enquiries.hk@transmedicgroup.com
Last updated on June 25, 2024
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.
